Visit
The EORTC CLTF 20-21 Meeting took place from 14-16 October, 2021, as both a live meeting in Marseille, France, and as a virtual event. This meeting covered the latest updates in cutaneous lymphoma
EORTC CLTF 2021
Find out more about novel developments in R/R #Hodgkin lymphoma, including the promise of checkpoint inhibitors, bispecifics and CAR-T cells, in our exclusive interview with Graham Collins (@graham74GC):
šhttp://ow.ly/9aXO50LM8BPš
#LymSM #ImmunoOnc #HemOnc #ISHL12
#ESHCML2022 | Camille Kockerols (@asznl) comments on the efficacy and tolerability of asciminib in patients with CML who are intolerant or resistant to TKIs:
š„: http://ow.ly/1Nxh50LM89Q
@ESHaematology #LeuSM #CMLsm #HemOnc
Letās learn from the non-conclusive studies reported at #ASH22 and congratulate all colleagues who took the challenge and dedicated time, efforts, ressources and energy to try to advance the field. A negative tweet is easy to write, but spending 5y to run a trial is another story https://twitter.com/Mohty_EBMT/status/1595293396297449472
We shouldnāt celebrate failure of a drug, celebrate learning instead because thereās always a path forward āIāve missed more than 9000 shots in my career. Iāve lost almost 300 gamesā¦Iāve failed over and over and over again in my life. And that is why I succeedā ā M Jordan #ASH22
Saad Kenderian (@kenderian_ss) of @MayoClinic discusses the current challenges and opportunities regarding CAR-T cell therapy and the tumor microenvironment at #SOHO22:
š„: http://ow.ly/Kf0Q50LM7L3
#HemOnc #ImmunoOnc #CARTcell
EORTC CLTF 2021
The EORTC CLTF 20-21 Meeting took place from 14-16 October, 2021, as both a live meeting in Marseille, France, and as a virtual event. This meeting covered the latest updates in cutaneous lymphoma
Find out more about novel developments in R/R #Hodgkin lymphoma, including the promise of checkpoint inhibitors, bispecifics and CAR-T cells, in our exclusive interview with Graham Collins (@graham74GC):
šhttp://ow.ly/9aXO50LM8BPš
#LymSM #ImmunoOnc #HemOnc #ISHL12
#ESHCML2022 | Camille Kockerols (@asznl) comments on the efficacy and tolerability of asciminib in patients with CML who are intolerant or resistant to TKIs:
š„: http://ow.ly/1Nxh50LM89Q
@ESHaematology #LeuSM #CMLsm #HemOnc
Letās learn from the non-conclusive studies reported at #ASH22 and congratulate all colleagues who took the challenge and dedicated time, efforts, ressources and energy to try to advance the field. A negative tweet is easy to write, but spending 5y to run a trial is another story https://twitter.com/Mohty_EBMT/status/1595293396297449472
We shouldnāt celebrate failure of a drug, celebrate learning instead because thereās always a path forward āIāve missed more than 9000 shots in my career. Iāve lost almost 300 gamesā¦Iāve failed over and over and over again in my life. And that is why I succeedā ā M Jordan #ASH22
Saad Kenderian (@kenderian_ss) of @MayoClinic discusses the current challenges and opportunities regarding CAR-T cell therapy and the tumor microenvironment at #SOHO22:
š„: http://ow.ly/Kf0Q50LM7L3
#HemOnc #ImmunoOnc #CARTcell
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
